Corcept Therapeutics Inc (NASDAQ: CORT) has a higher price-to-earnings ratio of 29.22x compared to its average ratio. CORT has 36-month beta value of 0.44. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 1 as “sell.”
The public float for CORT is 89.78M, and currently, short sellers hold a 23.67% ratio of that float. The average trading volume of CORT on July 04, 2024 was 1.17M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CORT) stock’s latest price update
Corcept Therapeutics Inc (NASDAQ: CORT) has seen a decline in its stock price by -1.74 in relation to its previous close of 31.56. However, the company has experienced a -1.87% decline in its stock price over the last five trading sessions. investorplace.com reported 2024-06-26 that While innovations such as artificial intelligence have become all the rage, there’s another type of technology – biotechnology – that deserves careful consideration for your portfolio. Indeed, if you haven’t considered the sector, it’s really time to focus on biotech stocks.
CORT’s Market Performance
Corcept Therapeutics Inc (CORT) has seen a -1.87% fall in stock performance for the week, with a -0.93% decline in the past month and a 20.90% surge in the past quarter. The volatility ratio for the week is 3.72%, and the volatility levels for the past 30 days are at 4.91% for CORT. The simple moving average for the last 20 days is -1.63% for CORT stock, with a simple moving average of 16.74% for the last 200 days.
Analysts’ Opinion of CORT
Many brokerage firms have already submitted their reports for CORT stocks, with Truist repeating the rating for CORT by listing it as a “Buy.” The predicted price for CORT in the upcoming period, according to Truist is $38 based on the research report published on November 06, 2023 of the previous year 2023.
SVB Securities, on the other hand, stated in their research note that they expect to see CORT reach a price target of $25. The rating they have provided for CORT stocks is “Market Perform” according to the report published on April 11th, 2023.
Piper Sandler gave a rating of “Overweight” to CORT, setting the target price at $27 in the report published on April 04th of the previous year.
CORT Trading at 8.65% from the 50-Day Moving Average
After a stumble in the market that brought CORT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.95% of loss for the given period.
Volatility was left at 4.91%, however, over the last 30 days, the volatility rate increased by 3.72%, as shares sank -7.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +36.77% upper at present.
During the last 5 trading sessions, CORT fell by -3.48%, which changed the moving average for the period of 200-days by -8.87% in comparison to the 20-day moving average, which settled at $31.41. In addition, Corcept Therapeutics Inc saw -4.53% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CORT starting from Robb Gary Charles, who sale 11,000 shares at the price of $32.49 back on Jul 01 ’24. After this action, Robb Gary Charles now owns 26,291 shares of Corcept Therapeutics Inc, valued at $357,390 using the latest closing price.
Guyer William, the Chief Development Officer of Corcept Therapeutics Inc, sale 10,000 shares at $32.49 during a trade that took place back on Jul 01 ’24, which means that Guyer William is holding 6,039 shares at $324,900 based on the most recent closing price.
Stock Fundamentals for CORT
Current profitability levels for the company are sitting at:
- 0.23 for the present operating margin
- 0.99 for the gross margin
The net margin for Corcept Therapeutics Inc stands at 0.23. The total capital return value is set at 0.22. Equity return is now at value 21.75, with 18.40 for asset returns.
Based on Corcept Therapeutics Inc (CORT), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at 1642.61. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is 34.05.
Currently, EBITDA for the company is 109.64 million with net debt to EBITDA at -1.21. When we switch over and look at the enterprise to sales, we see a ratio of 5.78. The receivables turnover for the company is 8.24for trailing twelve months and the total asset turnover is 0.8. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.18.
Conclusion
To put it simply, Corcept Therapeutics Inc (CORT) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
